Epidemiology and antifungal susceptibility of Candida species isolated from blood: Results of a 2-year multicentre study in Spain

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 24, Issue 1, 2005, Pages 23-30

  Peman J ^a   Canton E ^b   Gobernado, M ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; VORICONAZOLE;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BLOOD EXAMINATION; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDIASIS; CHILD; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; FUNGUS ISOLATION; HUMAN; INFANT; INTRAVENOUS CATHETER; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, FUNGAL; FEMALE; FUNGEMIA; HEALTH SURVEYS; HUMANS; INCIDENCE; INFANT; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PROBABILITY; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; SEX DISTRIBUTION; SPAIN;

EID: 13144253140     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10096-004-1267-5     Document Type: Article

References (50)

1. Beck-Sagué CM, Jarvis WR, and the National Nosocomial Infections Surveillance System (1993) Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. J Infect Dis 167:1247-1251
2. Abi-Said D, Anaissie E, Uzun O, Raad L, Pinzcowski H, Vartivarian S (1997) The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 24:1122-1128
3. Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP (1999) Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 29:239-244
4. Wey SB, Mori M, Pfaller MA et al (1988) Hospital-acquired candidemia: the attributable mortality and excess length of stay. Arch Intern Med 148:2642-2645
5. Wenzel RP, Edmond MB (2001) The impact of hospital-acquired bloodstream infections. Emerg Infect Dis 7:174-177
6. Pelz RK, Lipsett PA, Swoboda SM, Diener-West M, Powe NR, Brower RG, Perl TM, Hammond JM, Hendrix CW (2000) Candida infections: outcome and attributable ICU cost in critically ill patients. J Intensive Care Med 15:255-261
7. Pfaller MA, Diekema DJ (2002) Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility. J Clin Microbiol 40:3551-3557
8. Collin B, Clancy CJ, Nguyen MH (1999) Antifungal resistance in non-albicans Candida species. Drug Resistance Updates 3:9-14
9. St-Germain G, Laverdiere M, Pelletier R, Bourgault AM, Libman M, Lemieux C, Noel G (2001) Prevalence and antifungal susceptibility of 442 Candida isolates from blood and other normally sterile sites: results of a 2-year (1996 to 1998) multicenter surveillance study in Quebec, Canada. J Clin Microbiol 39:949-953
10. Sandven P (2000) Epidemiology of candidemia. Rev Iberoam Micol 17:73-81
11. Viscoli C, Girmenia C, Marinus A, Viscoli Collette L, Martino P, Vandercam B, Doyen C, Lebeau B et al (1999) Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 28:1071-1079
12. Launay O, Lortholary O, Bouges-Michel C, Jarrousse B, Bentata M, Guillevin L (1998) Candidemia: a nosocomial complication in adults with late-stage AIDS. Clin Infect Dis 26:1134-1141
13. Tumbarello M, Tacconelli E, De Gaetano Donati K, Morace G, Fadda G, Cauda R (1999) Candidemia in HIV-infected subjects. Eur J Clin Microbiol Infect Dis 18:478-483
14. National Committee for Clinical Laboratory Standards (1997) Reference method for broth dilution antifungal susceptibility testing of yeast. Approved standard M27-A. NCCLS, Wayne, PA
15. Sabo JA, Abdel-Rahman SM (2000) Voriconazole: a new triazole antifungal. Ann Pharmacother 34:1032-1043
16. Rex JH, Pfaller MA, Walsh TJ, Chaturvedi V, Espinel-Ingroff A, Ghannoum MA, Gosey LL, Odds FC et al (2001) Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev 14:643-658
17. Instituto Nacional de Estadística (2003) Censo de población y viviendas 2001. http://www.ine.es/prodyser/pubweb/folletocenso01/pags7-27.pdf
18. Abbas J, Bodey GP, Hanna HA, Mardani M, Girgawy E, Abi-Said D, Whimbey E, Hachem R et al (2000) Candida krusei fungemia. An escalating serious infection in immunocompromised patients. Arch Intern Med 160:2659-2664
19. Nguyen MH, Peacock JE Jr, Morris AJ, Tanner DC, Nguyen ML, Snydman DR, Wagener MM, Rinaldi MG, Yo VL (1996) The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med 100:617-623
20. Yamamura DL, Rotstein C, Nicolle LE, Ioannou S (1999) Candidemia at selected Canadian sites: results from the Fungal Disease Registry, 1992-1994. Can Med Assoc J 160:493-499
21. Fraser VJ, Jones M, Dunkel J, Storfer S, Medoff G, Dunagan WC (1992) Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis 15:414-421
22. Pemán J, Cantón E, Orero A, Viudes A, Frasquet J, Gobernado M (2002) Epidemiology of candidemia in Spain - multicenter study. Rev Iberoam Micol 19:30-35
23. Tortorano AM, Pemán J, Bernhardt H, Klingspor L, Kibbler CC, Faure O, Biraghi E, Cantón E, Zimmermann K, Seaton S, Grillot R, and the ECMM Working Group on Candidaemia (2004) Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis 23:317-322
24. Viudes A, Pemán J, Cantón E, Úbeda P, López-Ribot JL, Gobernado M (2002) Candidemia at a tertiary-care hospital: epidemiology, treatment, clinical outcome and risk factors for death. Eur J Clin Microbiol Infect Dis 21:767-774
25. Sota M, Ezpeleta C, Cisterna R (1999) Description of 165 episodes of fungemia: a multicenter study. Rev Iberoam Micol 16:30-35
26. Ainscough S, Barnes R, Gant V, Gransden WR (2000) Bloodstream infections due to Candida species in England and Wales: data from the ECMM epidemiological survey of candidaemia in Europe. Rev Iberoam Micol 17(Suppl 1):S143
27. Bernhardt H, Zimmermann K, Sissolak D, Schutt-Gerowitt H (2000) Epidemiological survey on candidemia in Europe: results of Germany and Austria. Rev Iberoam Micol 17(Suppl 1): S146
28. Grillot R, Faure O, Fruit J, Sendid B (2000) Working group: ECMM candidemia. ECMM prospective epidemiological survey of candidemia in Europe: report from France. Rev Iberoam Micol 17(Suppl 1):S144
29. Klingspor L, Tornquist E, Johansson A, Petrini B (2000) ECMM's survey of candidemia in Europe: report from Sweden. Rev Iberoam Micol 17(Suppl 1):S147
30. Tortorano AM, Biraghi E, Astolfi A, Ossi C, Tejada M, Farina C, Perin S, Bonaccorso C, Cavanna C, Raballo A, Grossi A, and the FIMUA Candidemia Study Group (2002) European Confederation of Medical Mycology (ECMM) prospective survey of candidaemia: report from one Italian region. J Hosp Infect 51:297-304
31. Karabinis A, Hill C, Leclercq B, Tancrede C, Baume D, Andremont A (1988) Risk factors for candidemia in cancer patients: a case-control study. J Clin Microbiol 26:429-432
32. Blumberg HM, Jarvis WR, Soucie JM, Edwards JE, Patterson JE, Pfaller MA, Rangel-Frausto MS, Rinaldi MG, Saiman OL, Wiblin RT, Wenzel RP, and the NEMIS Study Group (2001) Risk factors for Candida bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. Clin Infect Dis 33:177-186
33. Singh N (2001) Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices. Clin Infect Dis 33:1692-1696
34. Krcmery V Jr, Kovacicova G (2000) Longitudinal 10-year prospective survey of fungaemia in Slovak Republic: trends in etiology in 310 episodes. Diagn Microbiol Infect Dis 36:7-11
35. Pfaller MA, Jones RN, Doern GV, Sader HS, Messer SA, Houston A, Coffman S, Hollis RI (2000) Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998. Antimicrob Agents Chemother 44:747-751
36. Gómez J, Baños V, Simarro E, Ruiz J, Requena L, Pérez J, Canteras M, Valdés M (2001) Nosocomial fungemias in a general hospital. Epidemiology and prognostic factors. Prospective study 1993-1998. Enferm Infecc Microbiol Clin 19:304-307
37. Rodríguez-Tudela JL, Cuenca-Estrella M (1999) A multicenter study on fungemia caused by yeasts in Spain (April-June 1997). A work group to study fungemia. Rev Clin Esp 199:356-361
38. Sandven P, Bevanger L, Digranes A, Gaustad P, Haukland HH, Steinbakk M (1998) Constant low rate of fungemia in Norway, 1991 to 1996. J Clin Microbiol 36:3455-3459
39. Rennert G, Rennert HS, Pitlik S, Finkelstein R, Kitzes-Cohen R (2000) Epidemiology of candidemia, a nationwide survey in Israel. Infection 28:26-29
40. Oude Lashof AM, Donnelly JP, Meis JF, van derMeer JW, Kullberg BJ (2003) Duration of antifungal treatment and development of delayed complications in patients with candidaemia. Eur J Clin Microbiol Infect Dis 22:43-48
41. Krcmery V, Barnes AJ (2002) Non-albicans Candida spp. causing fungemia: pathogenicity and antifungal resistance. J Hosp Infect 50:243-260
42. Jarque I, Saavedra S, Martín G, Pemán J, Pérez Belles C, Sanz MA (2000) Delay of onset of candidemia and emergence of Candida krusei fungemia in hematologic patients receiving prophylactic fluconazole. Haematologica 85:441-443
43. Ostrosky-Zeichner L, Rex JH, Pappas PG, Hamill RJ, Larsen RA, Horowitz HW, Powderly WG, Hyslop N, Kauffman CA, Cleary J, Mangino JE, Lee J (2003) Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 47:3149-3154
44. Cuenca-Estrella M, Rodero L, Garcia-Effron G, Rodriguez-Tudela JL (2002) Antifungal susceptibilities of Candida spp. isolated from blood in Spain and Argentina, 1996-1999. J Antimicrob Chemother 49:981-987
45. Tortorano AM, Rigoni AL, Biraghi E, Prigitano A, Viviani MA, and the FIMUA-ECMM Candidaemia Study Group (2003) The European Confederation of Medical Mycology (ECMM) survey of candidaemia in Italy: antifungal susceptibility patterns of 261 non-albicans Candida isolates from blood. J Antimicrob Chemother 52:679-682
46. Hajjeh RA, Sofair AN, Harrison LH, Lyon GM, Arthington-Skaggs BA, Mirza SA, Phelan M, Morgan J et al (2004) Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 42:1519-1527
47. Pfaller MA, Messer SA, Hollis RJ, Jones RN, Diekema DJ (2002) In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob Agents Chemother 46:1723-1727
48. Marco F, Danes C, Almela M, Jurado A, Mensa J, de la Bellacasa JP, Espasa M, Martinez JA et al (2003) Trends in frequency and in vitro susceptibilities to antifungal agents, including voriconazole and anidulafungin, of Candida bloodstream isolates. Results from a six-year study (1996-2001). Diagn Microbiol Infect Dis 46:259-264
49. Pfaller MA, Messer SA, Boyken L, Huynh H, Hollis RJ, Diekema DJ (2002) In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods. Antimicrob Agents Chemother 46:3518-3521
50. Cantón E, Pemán J, Viudes A, Quindós G, Gobernado M, Espinel-Ingroff A (2003) Minimum fungicidal concentrations of amphotericin B for bloodstream Candida species. Diagn Microbiol Infect Dis 45:203-206